MANUEL KINGSLEY
Manuel is an expert in medical technology evaluation, development, and commercialization. He led company and technology acquisitions for Bard Medical and guided strategy development for the business. He has over 20 years of experience in the medical technology space including roles in corporate business development (executing mergers and acquisitions), guiding product development, and developing growth strategies. Manuel is the founder of Questus Healthcare Strategies which helps organizations and physician/academic inventors commercialize novel medical technologies. Since 2020, Manuel has been a team lead in RADx, NIH's COVID testing initiative. Before CR Bard, Manuel worked for McKinsey & Company’s strategy practice, Baxter Healthcare, Edwards Lifesciences, and IDEXX Labs. Manuel continually helps clients increase their understanding of customers, markets, and potential strategic acquirers. He is an industrial engineer by training, with an MBA from the University of North Carolina at Chapel Hill.
ELIAS CARO Elias is president and founder of Lab2Market PBC which is dedicated to training biomedical innovators in commercialization. At the Coulter Foundation as VP of Technology he oversees the Translational Partnership Programs at 16 universities. As Senior Executive VP of Beckman Coulter, he oversaw worldwide commercial operations, and previously was president of the biomedical division. For Coulter Corporation he managed companies in Japan, France, Belgium and Latin America. Caro holds a BA in Industrial Engineering, master’s degrees in polymer science and business, and is an AIMBE fellow.
Made with FlippingBook Ebook Creator